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Background: Vascular access is a necessity for patients with end-stage renal disease who need chronic intermittent
hemodialysis. According to Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, radial-cephalic (RC) and
brachial-cephalic (BC) arteriovenous fistulas (AVF) are the first and second choice for vascular access, respectively. If these
options are not possible, an autogenous brachial-basilic fistula in the upper arm (BBAVF) or a prosthetic brachial-
antecubital forearm loop (PTFE loop) may be considered. Until now, it was not clear which access type was preferable.
We have performed a randomized study comparing BBAVF and prosthetic implantation in patients without the
possibility for RCAVF or BCAVF.
Methods: Patients with failed primary/secondary access or inadequate arterial and/or venous vessels were randomized for
either BBAVF or PTFE loop creation. The numbers of complications and interventions were recorded. Kaplan-Meier
method was used to calculate primary, assisted-primary and secondary patency rates. The patency rates were compared
with the log-rank test. Complication and intervention rates were compared with the Mann-Whitney test.
Results: A total of 105 patients were randomized for a BBAVF or PTFE loop (52 vs 53, respectively). Primary and
assisted-primary 1-year patency rates were significantly higher in the BBAVF group: 46%  7.4% vs 22%  6.1% (P 
.005) and 87%  5.0% vs 71%  6.7% (P  .045) for the BBAVF and PTFE group, respectively. Secondary patencies were
comparable for both groups; 89%  4.6% vs 85%  5.2% for the BBAVF and PTFE group, respectively. The incidence rate
of complications was 1.6 per patient-year in the BBAVF group vs 2.7 per patient-year in the PTFE group. Patients in the
BBAVF group needed a total of 1.7 interventions per patient-year vs 2.7 per patient-year for the PTFE group.
Conclusion: These data show a significantly better primary and assisted-primary patency in the BBAVF group compared
with the PTFE group. Furthermore, in the BBAVF group, fewer interventions were needed. Therefore, we conclude that
BBAVF is the preferred choice for vascular access if RCAVF or BCAVF creation is impossible, or when these types of
access have already failed. ( J Vasc Surg 2008;47:395-401.)As the dialysis population gets older and has more comor-
bidities, the creation of an autogenous forearm fistula (radial-
cephalic arteriovenous fistula [RCAVF] or brachial-cephalic
arteriovenous fistula [BCAVF]) becomes more difficult.
Forearm vessels are not suitable for vascular access creation
if the diameter is too small, or the vessels are thrombosed or
diseased.1-5 Whenever forearm vessels are not suitable for
RCAVF/BCAVF creation or when these AVFs have failed,
the options for vascular access are either brachial-basilic
arteriovenous fistula (BBAVF) or the use of a prosthetic
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guidelines.6,7 Autogenous arteriovenous fistulas are known
for their better long-term patencies and lower thrombotic
complication rates compared with prosthetic implants.8-10
The advantages of prosthetic implants are the low primary
failure rate, no need for maturation, and ease of cannula-
tion.9 On the other hand, the infection and thrombosis
rates are reported higher in the literature compared with
the BBAVF.9,11,12 Because there is no consensus on which
of these types of vascular accesses is to be preferred, we
performed a randomized clinical trial between the BBAVF
and prosthetic brachial-antecubital forearm loop (PTFE
loop) graft to elucidate this problem. The purpose of our
study was to compare primary and secondary patency rates,
complications and interventions in the BBAVF, and pros-
thetic forearm loop vascular access.
METHODS
In this multicenter study, all patients in which previous
RCAVF/BCAVF had failed or in which creation of a
forearm fistula was impossible were included in one univer-
sity and two regional hospitals between October 1, 2003
395
JOURNAL OF VASCULAR SURGERY
February 2008396 Keuter et aland May 1, 2006. Patients were randomized between
BBAVF creation and creation of a brachial-antecubital fore-
arm loop graft. Informed consent was obtained from all
patients. The study was approved by the ethical committee
of the university as well as the regional hospitals.
Preoperative assessment. All patients in need of vas-
cular access in the three participating hospitals underwent
clinical examination and duplex scanning of the upper
extremity as a standard investigation before operation.
Clinical examination consisted of inspection and palpation
of the vessels of the arm, and measurement of blood pres-
sure on both sides. Duplex scanning of the arteries and
superficial veins was performed according to a standard
protocol by experienced vascular technicians. The angle of
the emitted Doppler ultrasound wave from the probe was
adjusted to 60 degrees to achieve the Doppler signal of the
strongest intensity. The anteroposterior internal diameter
of the vessel was measured using B-mode technique with a
proximal tourniquet to engorge the veins. Vessels were
diagnosed as obstructed when no Doppler signal could be
obtained. A radial artery and/or cephalic vein diameter of
less then 2 mm at the wrist and less then 3 mm at the elbow
were defined as unsuitable for the creation of a RCAVF or
BCAVF.7 Although, for the creation of a BBAVF, a diam-
eter of the basilic vein at the elbow of 3mmwas preferred, the
quality of the vein (nonstenotic and nondiseased) was consid-
ered more important for the decision whether the basilic vein
was suitable for BBAVF creation. Patients with small diameter
or thrombosed vessels, or failed RCAVF/BCAVF were asked
to participate in the study. Patients with an active local or
general infection and/or peripheral ischemia of the upper
extremity were excluded. After informed consent, the patients
were randomized by a computer system for either a brachial-
basilic arteriovenous fistula or a brachial-antecubital forearm
loop graft.
Surgical procedure. All procedures were performed
under local/regional or general anesthesia. All patients
received prophylactic antibiotic therapy according to the
local hospital standard.
Brachial-basilic arteriovenous fistulas were constructed
by making a continuous or interrupted longitudinal inci-
sion at the medial side of the upper arm to dissect the basilic
vein. A transverse incision 2 cm proximal to the elbow was
made to explore the brachial artery. The basilic vein was
mobilized proximally to the confluence with the deep
venous system. Side branches were ligated and, subse-
quently, the vein was transected as distal as possible. While
mobilizing the basilic vein, the medial brachial cutaneous
nerve was carefully spared to avoid nervous disturbances. At
the proximal end of the basilic vein, a bulldog clamp was
placed and, subsequently, the vein was gently dilated with a
saline injection. After local heparinization, the vein was
marked to prevent twisting. An anterolateral subdermal
tunnel was created with the use of a tunneling device at the
upper arm, with a diameter of at least 10 mm. Subse-
quently, the basilic vein was pulled through the tunnel and
an end-to-side vein-to-artery anastomosis was performedwith a running 7-0 polypropylene (Prolene) suture with a
limited arteriotomy of 7 mm.
For creation of a PTFE loop, thin-walled stretch PTFE
grafts (Gore-Tex, WL Gore & Associates, Flagstaff, Ariz)
with a wall thickness of 0.5 mm and an internal diameter of
6 mm, were positioned in a subcutaneous loop with the use
of a tunneling device in the forearm between the brachial
artery and a suitable elbow vein. Arterial and venous anas-
tomoses were created with running 7-0 polypropylene
(Prolene) sutures.
Access patency was confirmed peroperatively either by
palpation, Doppler examination, or angiography. All pa-
tients received 100 mg of aspirin per day unless already on
oral anticoagulation. Cannulation of the fistula was allowed
after wound healing and maturation (BBAVF), approxi-
mately 4 to 6 weeks for the BBAVF and 2 weeks after
surgery for the PTFE fistula.
Follow-up. All patients were followed for 12 months
after operation. Complications and interventions were re-
corded for this period. Monitoring (once a month) and
indications for interventions of the vascular access were
standardized. Interventions were done according to the
local hospitals standards. Nonmaturation (for BBAVF) was
defined as inability to cannulate the AVF. Clinical criteria
were used to detect thrombosis. Percutaneous transluminal
angioplasty (PTA) was done whenever a flow decrease of
more than 25% or 600 ml/min was measured during
dialysis (Transonic), or if patients had significantly longer
bleeding time or an increased venous pressure. A signifi-
cantly longer bleeding time is defined as a bleeding time of
150% of the patients’ usual bleeding time (which usually
varies from 5 to 15 minutes).
End points. End points were primary, assisted-primary,
and secondary patency for both types of fistula.
Statistical analysis. A power calculation was per-
formed before the start of the study to determine the
number of patients needed to demonstrate a difference in
patency between the two groups after 1 year follow-up of
25% with a power of 80% and an  of .05. In each group, 51
patients were needed. For the definition of incidence rate,
we used number of complications or interventions per
patient-year (py), the cumulative follow-up time of all
patients, and analyzed with the Mann-Whitney test. The
different patency rates were defined as described by Sidawy
et al.13 Primary patency was defined as the interval from the
time of access placement until any intervention designed to
maintain or reestablish patency, access thrombosis, or the
time of measurement of patency. Assisted-primary patency
is defined as the interval from the time of access placement
until access thrombosis or the time of measurement of
patency, including intervening manipulations designed to
maintain the functionality of a patent access. Secondary
patency was defined as the interval from the time of access
placement until access abandonment, thrombosis, or the
time of patencymeasurement including interveningmanip-
ulations designed to reestablish functionality in throm-
bosed access. Patency rates were calculated with the
Kaplan-Meier life-table analysis. The log-rank test was used
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were considered statistically significant when the P value
was less than .05. Patients with a patent fistula who died,
had successful kidney transplantation, or were withdrawn
from hemodialysis alive were censored.
RESULTS
One hundred seventeen patients were included in this
study, 12 of which were withdrawn before the surgical
procedure because of possibility to create a RCAVF after all
(n  7), death of the patient (n  2), improvement of
kidney function (n  2), and patient withdrawal (n  1).
Therefore, 105 patients were randomized, 53 of which for
a PTFE forearm loop graft. In all patients, peroperative
evaluation showed that it was possible to create either a
BBAVF or a PTFE forearm loop graft. Equal distributions
were seen regarding the peroperative patient characteristics
and the local risk factors (Table I). In spite of peroperative
evaluation, peroperatively basilic vein caliber appeared un-
suitable for creation of a basilic vein transposition in two
patients, and therefore, another type of vascular access was
created. In the PTFE group, it was decided not to create a
prosthetic forearm loop in two patients because of low
blood pressures. Therefore, 101 patients were eligible for
analysis of survival curves (PTFE forearm loop graft 51).
Mean follow-up time (SE) was 340 (11) vs 325 (15)
days for the BBAVF and PTFE group, respectively. Total
follow-up time was 39.3 py for the PTFE group and 41.0
py for the BBAVF group. Mean time to cannulation was 51
(9.9) days vs 60 (8.5) days in the PTFE and BBAVF
group, respectively.
Patency rates. A significant lower 1 year primary and
assisted-primary patency rate (SE) was seen in the PTFE
group compared with the BBAVF group, 22%  6.1% vs
46%  7.4% (P  .005; Fig 1) and 71%  6.7% vs 87% 
5.0% (P  .045; Fig 2), respectively. The secondary patency
rate after 1 year was comparable for the two groups, 85%
5.2% vs 89%  4.6% (P  .532; Fig 3) for the PTFE and
BBAVF group, respectively.
Twenty patients in the PTFE (12) and BBAVF (8)
group died of complications of their kidney failure with a






Male 26 (50%) 30 (57%)
Mean age (y) 60 66
Diabetes 20 (38%) 25 (47%)
Hypertension 21 (40%) 27 (51%)
Ischemic cardiac disease 21 (40%) 12 (23%)
Peripheral arterial obstructive disease 12 (23%) 14 (26%)
Cerebrovascular disease 3 (6%) 9 (16%)
Previously on hemodialysis 33 (63%) 29 (55%)
Previous vascular access 27 (52%) 8 (15%)
BBAVF, Brachial-basilic arteriovenous fistula; AVF, arteriovenous fistula.patent fistula during the follow-up period, three of whichdied within 1 week after operation (2 PTFE; 1 BBAVF).
Four patients underwent successful kidney transplantation
during the follow-up period, three of which in the BBAVF
group.
Complications. Twenty-two early complications (30
days of operation) occurred in 18 patients. They consisted of
hematoma (PTFE 1; BBAVF 2), thrombosis (PTFE 8; BBAVF
2), ischemia (PTFE 2), and infection (PTFE 6; BBAVF; 1). In
two patients (PTFE 1; BBAVF 1), early thrombosis led to
definitive failure of the access.
Nonmaturation occurred in two patients. These fistulas
could be saved by multiple PTAs and a surgical revision of
the anastomosis. Significantly, more infections (P  .031)
Fig 1. Primary patency rates of the brachial-basilic arteriovenous
fistula (BBAVF) and prosthetic arteriovenous fistula (AVF).
Fig 2. Assisted-primary patency rates of the brachial-basilic arte-
riovenous fistula (BBAVF) and prosthetic arteriovenous fistula
(AVF).and thrombotic events (P  .001) were seen in the PTFE
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was significantly higher in the PTFE group with 2.7 com-
plications/py (n 104) compared with the BBAVF group
with 1.6 complications/py (n  65) (P  .001). High
output cardiac failure was not seen in these patient groups.
Interventions. The incidence rates for interventions
was 2.7 interventions/py (n 104) for the PTFE group vs
1.7 interventions/py (n  70) for the BBAVF group (P 
.018). In Table III, the different types of interventions are
outlined. Significantly more surgical thrombectomies were
needed in the PTFE group (P .001). Two PTAs (subcla-
vian artery) and two banding procedures with flow reduc-
tion were needed for ischemic complications in the PTFE
group. In the BBAVF group, three PTAs (subclavian and
brachial artery), one stent placement (subclavian artery),
two proximalizations of the arteriovenous anastomosis14
and two banding procedures were performed. Eventually,
one fistula in the BBAVF group was ligated due to persis-
tent ischemia after proximalization of the arteriovenous
anastomosis.
DISCUSSION
These data show that a BBAVF needs fewer interven-
tions to prevent failure compared with prosthetic (PTFE)
forearm grafts. In addition, incidence rates for thrombosis
and infection are significantly better.
As the dialysis population becomes older (with various
comorbidity), the need for secondary and tertiary access,
including BBAVFs and prosthetic implants, will grow.
There is still no consensus which type of access is to be
preferred as randomized trials on this subject are lacking.
Although the surgical procedure for BBAVF creation
may be more difficult compared with prosthetic graft im-
plantation, only in two patients (3.9%) in this study it was
Fig 3. Secondary patency rates of the brachial-basilic arterio-
venous fistula (BBAVF) and prosthetic arteriovenous fistula
(AVF).not possible to perform a BBAVF because of small brachialartery diameter. Similarly, in the PTFE group, it was also
impossible to create a forearm loop graft in two patients
(3.8%). The cause for this was low blood pressure in both
patients.
One of the main disadvantages of BBAVFs is matura-
tion failure. The incidence of nonmaturation has been
reported within the range of 0% to 38%, although many
reports lack information on this issue.15 Hakaim reported
adequate maturation in a population with predominantly
diabetics.16 In our study, the nonmaturation rate was low,
which is in line with the lowest figures from the literature.
Nonmaturation of a BBAVF also has a lower incidence as
compared with the RCAVF,15,17 which can be explained by
the pristine condition of the basilic vein, which is protected
from iatrogenic damage due to its deep location in the
upper arm compared with the cephalic vein which has a
more superficial localization. Another advantage of the
BBAVFmay be the proximal location; therefore, the basilic
vein more often has a sufficient diameter (3 mm) for
creation of an AVF. When the diameter is smaller than 3
mm, a two-stage procedure may be advocated, with en-
hancement of diameters in first instance and superficializa-
tion in a second stage. In our study, all patients underwent
a one-stage procedure with good early and late results. In
this study population, infection occurred almost exclusively
in the PTFE grafts. Most infections presented within 30
days after operation, indicating peroperative contamina-
tion. Cannulation-related infection, as described in the
literature, has not been found.18 In a recent review, infec-
tion rate is reported as 3.6%.15 We found similar percent-
ages as seen by Coburn et al who described a higher
infection rate in the PTFE group in their retrospective
study of BBAVF and PTFE grafts.8
Surveillance with access flow monitoring has been ad-
vocated by recent American and European guidelines. A
significant flow decrease (25%) or low flow (600ml/min)
was themain reason for pre-emptive PTA.More PTAs were
needed in the PTFE group, indicating a high incidence of
stenosis formation. With this intensive surveillance and
treatment protocol assisted-primary patencies were well
acceptable for both BBAVF and prosthetic grafts.
Ischemic complications and intervention rates for isch-
emia were similar for both groups. These figures are compa-
rable with the rates found in the literature,15,18,19 although
incidence rates might be underestimated, as has recently
been shown, when using specific questionnaires for pa-
tients, focusing on ischemic complaints.20
High-output cardiac failure is one of the feared com-
plications of upper arm fistulas in this predisposed patient
population. Up to 75% of the end-staged renal disease pa-
tients already has left ventricular hypertrophy even before
hemodialysis.21 Due to the high access flows the cardiac load
increases and may induce cardiac failure eventually.22-24
High-output cardiac failuremay occur in high-flowAVFs, but
was not observed in our patients.15
The primary patency rates of both groups were lower
compared with the literature.9,11,12,16,18,19,25-30 These low
primary patency rates can be explained by before-mentioned
, inci
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stage due to close monitoring of the arteriovenous fistulas.
It is known that interventions with PTA or surgical revision
to correct stenosis reduces the rate of AVF thrombosis.31-34
These interventions have also the supplementary economic
impact of reducing emergency admissions due to access
thrombosis, reducing the need for central venous catheters
with their attendant complications, and preventing un-
derdialysis with its associated morbidity and mortality
rates.35 Therefore, pre-emptive interventions in fistulas
at risk for thrombosis at the current time is more a
standard than an acceptance, which results in lower
primary but higher assisted-primary and secondary pa-
tency rates.
More interventions were needed in the PTFE group
compared with the BBAVF group. This could be partly
explained by the pre-emptive interventions, as a result of
surveillance and close monitoring. The total number of
interventions was done in a smaller group of patients in the
BB-AVF group compared with the PTFE group (24 pa-
tients vs 36 patients, respectively). Some patients needed
more interventions than others, but this number of patients
was limited. For example two patients needed several PTAs
in the BBAVF group, one patient needed seven and the
other patient needed thirteen. These patients may con-
found the data. Nevertheless, overall fewer interventions
Table II. Number of complications per patient-year in BB
BBAVF








Flow decrease 29 .707
Venous hypertension 2 .049
Total complications 65 1.585
BBAVF, Brachial-basilic arteriovenous fistula; AVF, arteriovenous fistula; IR
*Indicates statistical significance.











BBAVF, Brachial-basilic arteriovenous fistula; AVF, arteriovenous fistula; IR
*Indicates statistical significance.were needed in the BBAVF group. The median time tointervention is significantly longer in the BBAVF, with
similar secondary patency rates after 1 year of follow-up,
but with significantly less interventions needed in the
BBAVF group. Similar results were seen from a randomized
study in which prosthetic implants were compared to
RCAVFs.12
It remains disputable whether an autogenous AVF with
the risk for nonmaturation should always be preferred in an
elderly population with various comorbidities like diabetes
and PAOD, of which 50% dies within 2 years.36 One could
argue to implant PTFE grafts in these patients with accessibil-
ity for cannulation within weeks.6 However, as patients are
referred in an early stage, and surgical experiencewith BBAVF
creation is sufficient, our preference would be the BBAVF
because of low intervention rates and long thrombosis-free
interval with high secondary patency rates after 1 year of
follow-up. In addition, the total costs of access-related hospi-
tal admissions and revisions may be lower in patients with
BBAVFs, due to the fewer interventions needed. Whenever
BBAVFs fail, it is still possible to create a prosthetic graft
fistula in most patients.37
Limitations of the study were the relatively short
follow-up time, although a significantly better primary
and assisted-primary patency was already shown after 1
year. It is not known if longer follow-up periods might
influence the secondary patency. However, graft deteri-
vs prosthetic AVF group
Prosthetic AVF












vs prosthetic AVF group
Prosthetic AVF
(n  51) IR P
0 61 1.564 .096
3 23 .590 .001*
0 10 .256 .371
8 2 .051 .245
9 0 0 .131
2 .051 .119
9 6 .154 .079
7 104 2.667 .018*










, incioration due to repetitive cannulation, might result in
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longer follow-up period.
CONCLUSION
In this prospective, randomized study, we found that
after BBAVF creation, the need for intervention to prevent
failure of the access occurs later and the number of inter-
ventions needed is less compared with prosthetic graft
implantation, which corresponds to a significantly better
primary as well as assisted-primary patency for the BBAVF.
Secondary patencies are comparable between both access
types. Therefore, we conclude that BBAVF creation is the
preferred option for a tertiary vascular access in hemodial-
ysis patients.
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